Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2104687 | 0.85 | CYP2C9 (0.52) | CYP2C9CYP2C19ALDH1A1CYP1A2SLC6A4 | |
| SCHEMBL7691846 | 0.83 | ALDH1A1 (0.40) | CYP2C9CYP2C19ALDH1A1CYP1A2KMT2A | |
| SCHEMBL2105728 | 0.82 | CYP2C9 (0.48) | CYP2C9CYP2C19ALDH1A1CYP1A2SLC6A4 | |
| SCHEMBL27433425 | 0.80 | AOC3 (0.48) | CYP2C9CYP2C19ALDH1A1CYP1A2SLC6A4 | |
| SCHEMBL2104678 | 0.80 | CYP2C9 (0.47) | CYP2C9CYP2C19ALDH1A1CYP1A2SLC6A4 | |
| SCHEMBL6680380 | 0.80 | ALDH1A1 (0.61) | CYP2C9CYP2C19ALDH1A1CYP1A2SLC6A4 | |
| SCHEMBL30575781 | 0.80 | ALDH1A1 (0.50) | CYP2C9CYP2C19ALDH1A1CYP1A2SLC6A4 | |
| SCHEMBL6683461 | 0.80 | ALDH1A1 (0.50) | CYP2C9CYP2C19ALDH1A1CYP1A2SLC6A4 | |
| SCHEMBL21409565 | 0.79 | SLC6A4 (0.54) | CYP2C9CYP2C19ALDH1A1CYP1A2SLC6A4 | |
| SCHEMBL2126034 | 0.79 | ALDH1A1 (0.54) | CYP2C9CYP2C19ALDH1A1CYP1A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111233786-B | Benzene sulfonamide compound containing five-membered heterocycle and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2021-11-26 | — | — | CN | claimed |
| CN-111233786-A | Benzene sulfonamide compound containing five-membered heterocycle and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2020-06-05 | — | — | CN | claimed |
| EP-1673337-B1 | Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics | SANOFI SA (FR) | 2011-11-23 | — | — | EP | claimed |
| EP-1590321-B1 | ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY | SANOFI AVENTIS (FR) | 2010-04-28 | — | — | EP | claimed |
| US-7696374-B2 | Arylalklcarbamate derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-13 | — | — | US | claimed |
| US-7632850-B2 | 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS | SANOFI-AVENTIS (FR) | 2009-12-15 | — | — | US | claimed |
| US-20060223805-A1 | Arylalklcarbamate derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-05 | — | — | US | claimed |
| EP-1673337-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-06-28 | — | — | EP | claimed |
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | SANOFI-AVENTIS (FR) | 2006-01-19 | — | — | US | claimed |
| EP-1590321-A2 | ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY | Sanofi-Aventis (FR) | 2005-11-02 | — | — | EP | claimed |
| WO-2005033066-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-04-14 | — | — | WO | claimed |
| WO-2004067498-A2 | ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2004-08-12 | — | — | WO | claimed |
| US-4021421-A | ENZYME INDUCING ACTIVITY | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-05-03 | — | — | US | claimed |
| CN-110234627-B | Pyridone compound and agricultural/horticultural bactericide containing pyridone compound as active ingredient | 三井化学植保株式会社 | 2023-09-01 | — | — | CN | disclosed |
| EP-3611165-B1 | PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT | MITSUI CHEMICALS CROP & LIFE SOLUTIONS INC (JP) | 2023-08-16 | — | — | EP | disclosed |
| EP-3575286-B1 | PYRIDONE COMPOUND AND BACTERICIDE FOR AGRICULTURAL AND HORTICULTURAL USE, WHICH USES SAID COMPOUND AS ACTIVE INGREDIENT | MITSUI CHEMICALS AGRO INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| EP-0603225-A1 | PROCESS FOR PRODUCING -g(a)-CHLOR-METHYLEN-TRIORGANYLPHOSPHORANE DERIVATES. | BASF AG (DE) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993005053-A1 | PROCESS FOR PRODUCING α-CHLOR-METHYLEN-TRIORGANYLPHOSPHORANE DERIVATES | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-18 | — | — | WO | disclosed |
| EP-0498680-A1 | New beta-amino-alpha-hydroxycarboxylic acids and their use | Sankyo Company Limited (JP) | 1992-08-12 | — | — | EP | disclosed |
| US-4045433-A | SEDATIVES | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C5 | CYP2C9 449/4885CYP2C19 543/4885ALDH1A1 2358/4885 |
| US-20060223805-A1 | Arylalklcarbamate derivatives, preparation method thereof and use of same in therapeutics | GBA1, NAT1, AADAC | CYP2C9 454/4885CYP2C19 1169/4885ALDH1A1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.